Documentos relacionados

1. A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation.
2. Epithelial 5-HT₄ Receptors as a Target for Treating Constipation and Intestinal Inflammation.
3. Déjà-vu? Neural and behavioural effects of the 5-HT₄ receptor agonist, prucalopride, in a hippocampal-dependent memory task.
4. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT₄ Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.
5. Genotoxicity and carcinogenicity risk assessment of prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist.
6. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation.
7. Prucalopride is no more effective than placebo for children with functional constipation.
8. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study.
9. Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers.
10. Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.